Supplementary Figure 4 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), José Baselga(Novartis (Switzerland)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Theresa Zhang, Sriram Sathyanarayanan(Boston Biomedical Research Institute), Johanna C. Bendell(Dana-Farber Cancer Institute), Youyuan Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sharda Jha(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Winter(Dana-Farber Cancer Institute), Jason P. Frazier(Rosetta Stone (United States)), Mark N. Stein(Cornell University), Richard A. Klinghoffer(Tempus Labs (United States)), Irene Braña(Vall d'Hebron Institute of Oncology), Ann Leighton-Swayze, Andrés Cervantes(INCLIVA Health Research Institute), Desamparados Roda, Brian B. Haines(Boston Biomedical Research Institute)
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k